GDUFA II began with a much higher first-cycle ANDA approval rate than has been seen in previously, a promising sign as the US FDA works to increase generic approvals in the hopes of lowering drug prices.
The agency's Office of Generic Drugs reported 26 full first-cycle approvals out of 87 issued in October, the first month...







